血管内皮抑制素治疗胃癌术后肝转移的疗效分析

Effect of endostatin on postoperative liver metastasis of gastric cancer

摘要:

目的 探讨血管内皮抑制素治疗胃癌术后肝转移的疗效。方法 选取2015 年2 月—2016 年6 月 六安市中医院收治的68 例胃癌术后肝转移患者，将患者分为对照组及研究组，各34 例。对照组采用奥沙 利铂肝动脉持续灌注联合经导管动脉栓塞化疗，研究组在对照组基础上加用重组人血管内皮抑制素肝动脉 持续灌注治疗，比较两组患者临床疗效、1 年生存率、疾病控制率、无疾病进展生存率、总生存率、不良 反应发生率及治疗前后血管内皮生长因子（VEGF）水平的变化。结果 实验组治疗总有效率、1 年生存 率、疾病控制率、无疾病进展生存率及总生存率高于对照组（P <0.05）；实验组治疗后VEGF 水平下降程 度高于对照组（P <0.05）；对照组和实验组治疗前后的VEGF 水平组内比较，差异有统计学意义（P <0.05）。 结论 血管内皮抑制素治疗胃癌术后肝转移的疗效值得肯定，患者生存率进一步提升且VEGF 水平下降，用 药过程中不良反应发生率低，值得临床推广使用。

Abstract:

Objective To investigate the effect of endostatin on postoperative liver metastasis of gastric cancer. Methods Sixty-eight patients with liver metastases after gastric cancer treated in our hospital from February 2015 to June 2016 were divided into control group (n = 34 cases) and study group (n = 34 cases) by pair comparison method. The control group received continuous reperfusion with oxaliplatin through hepatic artery combined with transcatheter arterial chemoembolization (TACE) treatment, and the study group was treated with continuous hepatic arterial infusion of recombinant human endostatin on the basis of the control group. Clinical efficacy, 1-year survival, and disease control were compared between the two groups. The total effective rate, progression-free survival, overall survival, incidence of adverse reactions, and changes in serum vascular endothelial growth factor (VEGF) levels were compared before and after treatment. Results The total effective rate, 1-year survival rate, disease control rate, progression-free survival rate, and overall survival rate of the study group were higher than those of the control group (P < 0.05); the decreasing degree of VEGF in the study group was more than that in the control group (P < 0.05);there was significant difference in the level of vascular endothelial growth factor between the control group and the study group before and after treatment (P < 0.05). Conclusions The therapeutic effect of endostatin on postoperative liver metastasis of gastric cancer is worthy of recognition. The survival rate of patients is further improved and the serum VEGF level is significantly decreased. The incidence of adverse reactions during the course of drug use is low and it has to be popularized in future clinical treatment.